Nervius (Pramipexole Dihydrochloride Monohydrate)

Pramipexole, the active ingredient in Nervius, is a dopamine agonist presented as an oral tablet for oral use. It stimulates dopaminergic activity in the brain and is employed in the management of Parkinson's disease and restless legs syndrome in adult patients through selective D2/D3 receptor activation to improve motor symptoms and reduce uncomfortable sensations.

GNH USA supplies Nervius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality assurance, regulatory compliance and reliable logistics for global distribution.

Pramipexole is a dopamine agonist used in movement‑disorder therapy.

Parkinson's disease: improves motor control and reduces rigidity and bradykinesia. Restless legs syndrome: lessens leg discomfort and the urge to move during rest. Parkinson's disease with motor fluctuations: decreases "off" periods and enhances overall daily functioning.

Pramipexole may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: sensation of light‑headedness, especially on standing. - Somnolence: increased sleepiness or fatigue. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Hallucinations: visual or auditory disturbances that may require medical attention. - Impulse control disorders: compulsive gambling, shopping, or hypersexuality. - Severe hypotension: marked drop in blood pressure leading to fainting.

When prescribing pramipexole, several precautions should be observed to ensure safe use. - Renal function: dose adjustment is required in patients with severe renal impairment. - Elderly patients: monitor for orthostatic hypotension and increased sedation. - Psychiatric history: watch for emergence of hallucinations or impulse control issues. - Concomitant MAO‑B inhibitors: avoid combined use due to risk of excessive dopaminergic stimulation. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Store at ambient temperature: keep in original container, protect from moisture and light.

Pramipexole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): may antagonize pramipexole’s effect. - Strong CYP2D6 inhibitors (e.g., quinidine): increase pramipexole plasma concentrations.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect may require blood pressure monitoring. - Other dopamine agonists: combined use can heighten risk of side effects such as nausea or impulse control disorders. - SSRIs or SNRIs: may increase the likelihood of impulse control problems.